A Phase 1/2, Randomized, Placebo-controlled, Observer-blinded Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A Multivalent Group B Streptococcus Vaccine In Healthy Adults 18 To 49 Years Of Age

Trial Profile

A Phase 1/2, Randomized, Placebo-controlled, Observer-blinded Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A Multivalent Group B Streptococcus Vaccine In Healthy Adults 18 To 49 Years Of Age

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 Jul 2017

At a glance

  • Drugs Multivalent group B streptococcus vaccine-Pfizer (Primary)
  • Indications Streptococcal infections
  • Focus Adverse reactions; First in man
  • Sponsors Pfizer
  • Most Recent Events

    • 28 Jun 2017 Planned End Date changed from 15 May 2018 to 13 Jun 2018.
    • 28 Jun 2017 Planned primary completion date changed from 15 May 2018 to 13 Jun 2018.
    • 28 Jun 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top